Vorinostat is the first HDAC inhibitor approved by the Food and Drug Administration (FDA) to treat advanced cutaneous T-cell lymphoma (CTCL)5, 6. This evidence concerns the gene HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma.